TY - JOUR
T1 - Reconsidering the Utility of Race-Specific Lung Function Prediction Equations
AU - Baugh, Aaron D.
AU - Shiboski, Stephen
AU - Hansel, Nadia N.
AU - Ortega, Victor
AU - Barjakteravic, Igor
AU - Barr, R. Graham
AU - Bowler, Russell
AU - Comellas, Alejandro P.
AU - Cooper, Christopher B.
AU - Couper, David
AU - Criner, Gerard
AU - Curtis, Jeffrey L.
AU - Dransfield, Mark
AU - Ejike, Chinedu
AU - Han, Mei Lan K.
AU - Hoffman, Eric
AU - Krishnan, Jamuna
AU - Krishnan, Jerry A.
AU - Mannino, David
AU - Paine, Robert
AU - Parekh, Trisha
AU - Peters, Stephen
AU - Putcha, Nirupama
AU - Rennard, Stephen
AU - Thakur, Neeta
AU - Woodruff, Prescott G.
N1 - Funding Information:
Supported by NHLBI grants U01HL137880, K24HL137013, K23HL125551, HL137013, and F32HL158160. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C) and grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762) and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan. The above entities had no role in the analysis or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
Publisher Copyright:
© 2022 by the American Thoracic Society.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Rationale: African American individuals have worse outcomes in chronic obstructive pulmonary disease (COPD). Objectives: To assess whether race-specific approaches for estimating lung function contribute to racial inequities by failing to recognize pathological decrements and considering them normal. Methods: In a cohort with and at risk for COPD, we assessed whether lung function prediction equations applied in a racespecific versus universal manner better modeled the relationship between FEV1, FVC, and other COPD outcomes, including the COPD Assessment Test, St. George's Respiratory Questionnaire, computed tomography percent emphysema, airway wall thickness, and 6-minute-walk test. We related these outcomes to differences in FEV1 using multiple linear regression and compared predictive performance between fitted models using root mean squared error and Alpaydin's paired F test. Measurements and Main Results: Using race-specific equations, African American individuals were calculated to have better lung function than non-Hispanic White individuals (FEV1, 76.8% vs. 71.8% predicted; P = 0.02). Using universally applied equations, African American individuals were calculated to have worse lung function. Using Hankinson's Non-Hispanic White equation, FEV1 was 64.7% versus 71.8% (P<0.001). Using the Global Lung Initiative's Other race equation, FEV1 was 70.0% versus 77.9% (P<0.001). Prediction errors from linear regression were less for universally applied equations compared with race-specific equations when examining FEV1% predicted with the COPD Assessment Test (P<0.01), St. George's Respiratory Questionnaire (P<0.01), and airway wall thickness (P<0.01). Although African American participants had greater adversity (P<0.001), less adversity was only associated with better FEV1 in non-Hispanic White participants (P for interaction = 0.041). Conclusions: Race-specific equations may underestimate COPD severity in African American individuals.
AB - Rationale: African American individuals have worse outcomes in chronic obstructive pulmonary disease (COPD). Objectives: To assess whether race-specific approaches for estimating lung function contribute to racial inequities by failing to recognize pathological decrements and considering them normal. Methods: In a cohort with and at risk for COPD, we assessed whether lung function prediction equations applied in a racespecific versus universal manner better modeled the relationship between FEV1, FVC, and other COPD outcomes, including the COPD Assessment Test, St. George's Respiratory Questionnaire, computed tomography percent emphysema, airway wall thickness, and 6-minute-walk test. We related these outcomes to differences in FEV1 using multiple linear regression and compared predictive performance between fitted models using root mean squared error and Alpaydin's paired F test. Measurements and Main Results: Using race-specific equations, African American individuals were calculated to have better lung function than non-Hispanic White individuals (FEV1, 76.8% vs. 71.8% predicted; P = 0.02). Using universally applied equations, African American individuals were calculated to have worse lung function. Using Hankinson's Non-Hispanic White equation, FEV1 was 64.7% versus 71.8% (P<0.001). Using the Global Lung Initiative's Other race equation, FEV1 was 70.0% versus 77.9% (P<0.001). Prediction errors from linear regression were less for universally applied equations compared with race-specific equations when examining FEV1% predicted with the COPD Assessment Test (P<0.01), St. George's Respiratory Questionnaire (P<0.01), and airway wall thickness (P<0.01). Although African American participants had greater adversity (P<0.001), less adversity was only associated with better FEV1 in non-Hispanic White participants (P for interaction = 0.041). Conclusions: Race-specific equations may underestimate COPD severity in African American individuals.
KW - chronic obstructive pulmonary disease
KW - health disparities
KW - racism
KW - respiratory function tests
UR - http://www.scopus.com/inward/record.url?scp=85127207629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127207629&partnerID=8YFLogxK
U2 - 10.1164/rccm.202105-1246OC
DO - 10.1164/rccm.202105-1246OC
M3 - Article
C2 - 34913855
AN - SCOPUS:85127207629
VL - 205
SP - 819
EP - 829
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
SN - 1073-449X
IS - 7
ER -